Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$HLS {{ '2017-12-12T13:23:46+0000' | timeago}} • Announcement

$HLS appointed Nancy Schlichting as an independent director, effective Dec. 11, 2017. With this appointment, the Board will expand to 11 directors. Schlichting currently serves on the boards of $WBA and $HRC.

$AGN {{ '2018-02-06T21:23:10+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q4 2017 Highlights

$AGN {{ '2018-02-06T17:23:26+0000' | timeago}} • Announcement

For FY18, $AGN expects its total net revenues to be in the range of $15.0 -15.3Bil and net loss per share is expected to be about $2.27-1.52. The company expects its 1Q18 total net revenues to be about $3.5-3.6Bil and net loss per share of about $1.27-1.07.

$AGN {{ '2018-02-06T17:17:53+0000' | timeago}} • Announcement

Drugmaker $AGN reported a profit for 4Q17 on strong demand for Botox. Net earnings came to $3.05Bil, or $8.88 per share, compared with a  year-earlier loss of $70.2MM, or $0.20 loss per share. Adj. EPS was $4.86. Revenue rose 12% YoY to $4.33Bil, helped by the sales growth in drugs like Botox, Alloderm and Juvederm collection.

$AGN {{ '2018-02-01T13:45:14+0000' | timeago}} • Announcement

$AGN agreed to pay $700MM to $TEVA to settle their working capital dispute arbitration. Teva expects to receive this payment from Allergan in 1Q18 and use this amount for repaying a portion of its term loan debt. As of Jan. 12, 2018, Allergan owns 6.8% of Teva shares.

$HCA {{ '2018-01-30T22:09:42+0000' | timeago}} • Infographic

$HCA HCA Healthcare Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$LGND {{ '2018-01-22T15:49:24+0000' | timeago}} • Announcement

Pharma company $LGND has signed a license agreement with Ferring Pharmaceuticals, under which the latter will get access to its therapeutic antibody platform OmniAb, for discovery of fully human mono- and bispecific antibodies. Ligand will receive platform access fees, milestone payments and royalties.

$LGND {{ '2018-01-19T15:51:19+0000' | timeago}} • Announcement

$LGND announced initiation of a program to develop contrast agents with reduced renal toxicity. Contrast agents are injectable solutions used during diagnostic imaging procedures. $LGND plans to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$LGND {{ '2018-01-11T17:54:53+0000' | timeago}} • Announcement

Pharma company $LGND has signed a license agreement with Glenmark Pharmaceuticals, allowing the latter to use the OmniAb platform for discovery of antibodies. For products incorporating OmniAb antibodies, Ligand will receive annual platform access payments and royalties, while the programs will be entirely funded by Glenmark.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$MSA {{ '2018-01-09T19:42:03+0000' | timeago}} • Announcement

$MSA BoD declared 1Q18 dividend of 35 cents per share on common stock. The dividend is payable March 10, 2018 to shareholders of record on February 14, 2018.

$SEM {{ '2018-01-09T18:17:01+0000' | timeago}} • Announcement

$SEM announced a JV agreement with Banner Health to combine operations of more than 38 physical therapy centers in Arizona and four acute inpatient rehabilitation hospitals in Phoenix. Banner Health will be the majority owner and $SEM will serve as managing partner.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$SEM {{ '2018-01-08T18:16:59+0000' | timeago}} • Announcement

$SEM expects consolidated net operating revenues for full year 2018 to be $5-5.2Bil. Adjusted EBITDA is expected to be $630-660MM. $SEM expects fully diluted income per common share for full year 2018 to be $0.97-1.12.

$MLNT {{ '2018-01-08T17:08:01+0000' | timeago}} • Announcement

$MLNT completed the acquisition of $MDCO’s infectious disease business. $MLNT also announced that $MDCO’s Mike McGuire has joined the new organization as SVP, Commercial, replacing Chief Commercial Officer, John Temperato, who left $MLNT to pursue other opportunities.

$MDCO {{ '2018-01-08T13:17:52+0000' | timeago}} • Announcement

Pharma firm $MDCO closed the sale of its infectious disease business to $MLNT for $215MM of guaranteed cash and 3.3 MM common shares of Melinta. The sale consideration also includes royalty payments of 5-25% on certain drug sales and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.

$THC {{ '2018-01-05T17:28:17+0000' | timeago}} • Announcement

$THC and St. Luke’s Hospital, an independent, non-profit healthcare provider, have entered into a definitive agreement for St. Luke’s to purchase Des Peres Hospital as well as Tenet-owned physician practices and other hospital-affiliated operations in St. Louis. The transaction is expected to be completed early in 2018.

$THC {{ '2018-01-04T22:16:28+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health plan to restructure their JV arrangements for three North Texas hospitals by spring of 2018. Baylor Scott & White will acquire $THC’s minority interest in Baylor Scott & White - Centennial and Baylor Scott & White - Lake Pointe. Baylor Scott & White - Sunnyvale will become part of Texas Health Ventures Group.

$LGND {{ '2018-01-03T14:25:12+0000' | timeago}} • Announcement

$LGND's partner HanAll Biopharma out-licensed antibody projects that were discovered by HanAll using $LGND’s OmniAb antibody discovery platform. The licensing events triggered $6MM of payments to $LGND. Including these payments, $LGND now anticipates total revenue for full year 2017 to be approx. $140MM with adjusted EPS to be $3.13-3.16.

Recent Transcripts
CHE | Earnings
February 15th 2018, 3:00pm
DVA | Earnings
February 13th 2018, 10:00pm
MD | Earnings
February 8th 2018, 3:00pm
AGN | Earnings
February 6th 2018, 1:30pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
CHE | Earnings
February 15th 2018, 3:00pm
DVA | Earnings
February 13th 2018, 10:00pm
MD | Earnings
February 8th 2018, 3:00pm
AGN | Earnings
February 6th 2018, 1:30pm
AlphaGraphics you may like